SCHEMBL26720249

SCHEMBL26720249

CC(C)(C)OP(C)(=O)COS(=O)(=O)C(F)(F)F

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12214858 0.84
SCHEMBL2496661 0.83 CA2 (0.31) CA2
SCHEMBL16382046 0.79
SCHEMBL12151452 0.78 CA2 (0.34) CA2
SCHEMBL12150262 0.78 TSHR (0.33) CA2
SCHEMBL10709884 0.75 CA2 (0.33) CA2
SCHEMBL8342228 0.75 CA2 (0.33) CA2
SCHEMBL8347883 0.73 TSHR (0.35) CA2
SCHEMBL13942500 0.72 CA2 (0.31) CA2
SCHEMBL3380154 0.71 CA2 (0.33) CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807658-B2 CD73 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2023-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11807658-B2 CD73 inhibitors ENTPD5, NT5E, ENTPD1 CA2 2826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.